Investors

AIM Rule 26 Information

This area of the web site contains all information which is required to be disclosed in accordance with Rule 26 of the AIM Rules.

Shareholder Information

Other Exchanges and Trading Platforms
Shares in Issue
Significant Shareholdings
Director Shareholdings
Shares Not in Public Hands
Restrictions in Transfer of AIM Securities
UK City Code on Takeovers and Mergers

see Shareholder Information

Advisors

see Advisors

Announcements and Notifications

see News

Q&A with LungLife AI's CEO, Paul Pagano

Half-year Report For The Six Months Ended 30 June 2023

Featured News

September 4, 2024

Data Supporting LungLB to be Presented at the Association for Molecular Pathology

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, is pleased to announce that our two abstract submissions to the Association for Molecular Pathology1 (AMP) have beenaccepted for both presentation at their flagship 2024 Annual Meeting & Expo in Vancouver, BC, Canada from November 19-23rd, and also for publication in the […]

• Read More

August 22, 2024

LLAI Interim Results 2024

LungLife AI, Inc. (the “Company” or “LungLife”) Half-year Report LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, announces its unaudited half-year report for the six months ended 30 June 2024. Strong progress with our LungLB® product Continued operational delivery : Financial Highlights: Commenting Paul Pagano, Chief Executive […]

• Read More

« Previous 1 2 3 4 5 6 … 36 Next »

More News